Oncotelic Therapeutics, a leading developer of TGF- therapeutic products for the treatment of cancer and virology, today provided an update on its ongoing trial for the treatment of patients with advanced melanoma. OTLC stock is on the verge to collapse, it’s trading at $0.127, lower than its all-time high. The objective of the trial is to evaluate the safety, efficacy, and tolerance of TASO-001 in combination with other antisense oligonucleotides for the treatment of patients with solid tumor cancer. RT-0151 is a first-generation ribonucleic Acid that has shown single-agent activity in multiple clinical trials. It is also being evaluated against COVID-19.
Oncotelic announces Phase 2 study, which shows a lot of good results including security and safety measures, that will provide better outcomes for future research. It will help the patients with Hodgkin’s disease. In the safety cohort, which received 140 mg/m2, the standard dose of OT-101 was well tolerated. The company has increased the dose to 190 mg/m2. Oncotelic’s lead product candidate, OT-101, is an antisense drug that targets the TGF-beta protein. It is currently in phase 3 clinical trials for the treatment of pancreatic cancer and glioblastoma. During its phase 2 clinical trials, OT-101 exhibited robust efficacy against various types of cancer, including melanoma and pancreatic cancer. It has also received orphan designation for these indications.